WR-1065, the active form of amifostine, protects HL-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 3, 2004, Pages 844-851

  Hatoum, Georges F ^a   Nevaldine, Barbara ^a   Bhavsar, Tej ^a   Phung, Quentin ^a   Hahn, Peter J ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Amifostine; Apoptosis; Etoposide; HL 60; PBMC; Radiation; WR 1065

Indexed keywords

BLOOD; CELLS; CHEMOTHERAPY; IONIZING RADIATION; MICROSCOPIC EXAMINATION;

APOPTOSIS; HEMATOPOIETIC LINEAGES;

ONCOLOGY;

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; ETOPOSIDE; PROTEIN P53; RADIOPROTECTIVE AGENT;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IONIZING RADIATION; MYELOID LEUKEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION PROTECTION;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASES; CELL SURVIVAL; ENZYME INHIBITORS; ETOPOSIDE; HL-60 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MERCAPTOETHYLAMINES; RADIATION-PROTECTIVE AGENTS;

EID: 2942525269     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.046     Document Type: Article

References (45)

1. Tubiana M., Carde P., Frindel E. Ways of minimising hematopoietic damage induced by radiation and cytostatic drugs - the possible role of inhibitors. Radiother Oncol. 29:1993;1-17
2. Schiller J.H., Storer B., Tutsch K., et al. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol. 21:1994;9-14
3. Leonard R.C. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br J Cancer. 84:2001;1437-1442
4. Wingard J.R., Moreb J.S., Gaa R.I. High-dose chemotherapy with autologous stem cell rescue as a treatment modality for breast cancer. Breast J. 5:1999;308-318
5. Kornek G.V., Ulrich-Pur H., Penz M., et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol. 19:2001;621-627
6. Kwasny W., Kornek G., Haider K., et al. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat. 63:2000;235-241
7. Jones D.V. Jr., Ashby M., Vadhan-Raj S., et al. Recombinant human thrombopoietin clinical development. Stem Cells. 16:1998;199-206
8. Bernstein S.H., Fay J.P., Christiansen N.P., et al. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide A phase I/II trial. Clin Cancer Res. 3:1997;1519-1526
9. Schwartsmann G., Mans D.R., Menke C.H., et al. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology (Huntington). 11:1997;24-29
10. Kornek G.V., Haider K., Kwasny W., et al. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Br J Cancer. 74:1996;1668-1673
11. Bernstein S.H., Christiansen N.P., Fay J.P., et al. Granulocyte- macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide A pilot trial. Exp Hematol. 24:1996;1363-1368
12. Vermorken J.B., ten Bokkel Huinink W.W., Mandjes I.A., et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy A European Cancer Center trial. Semin Oncol. 22:1995;16-22
13. Havlin K. A phase I/phase II trial of granulocyte colony-stimulating factor as bone marrow support in patients treated with vinorelbine (Navelbine) Study design and goals. Semin Oncol. 22:1995;38-40. ; discussion 41-34
14. Mayers C., Panzarella T., Tannock I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 91:2001;2246-2257
15. Schiedlmeier B., Schilz A.J., Kuhlcke K., et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum Gene Ther. 13:2002;233-242
16. Fruehauf S., Wermann K., Buss E.C., et al. Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer. Recent Results Cancer Res. 144:1998;93-115
17. Licht T., Gottesman M.M., Pastan I. Transfer of the MDR1 (multidrug resistance) gene Protection of hematopoietic cells from cytotoxic chemotherapy, and selection of transduced cells in vivo. Cytokines Mol Ther. 1:1995;11-20
18. Eckert H.G., Kuhlcke K., Schilz A.J., et al. Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). Bone Marrow Transplant. 25:2000;S114-S117
19. Eckert H.G., Stockschlader M., Just U., et al. High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood. 88:1996;3407-3415
20. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol. 13:1995;513-543
21. Gratiot-Deans J., Merino R., Nunez G., et al. Bcl-2 expression during T-cell development Early loss and late return occur at specific stages of commitment to differentiation and survival. Proc Natl Acad Sci U S A. 91:1994;10685-10689
22. Akgul C., Moulding D.A., Edwards S.W. Molecular control of neutrophil apoptosis. FEBS Lett. 487:2001;318-322
23. Chao J.R., Wang J.M., Lee S.F., et al. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol. 18:1998;4883-4898
24. Klampfer L., Zhang J., Nimer S.D. GM-CSF rescues TF-1 cells from growth factor withdrawal-induced, but not differentiation-induced apoptosis The role of BCL-2 and MCL-1. Cytokine. 11:1999;849-855
25. Moulding D.A., Quayle J.A., Hart C.A., et al. Mcl-1 expression in human neutrophils Regulation by cytokines and correlation with cell survival. Blood. 92:1998;2495-2502
26. Wang J.M., Chao J.R., Chen W., et al. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol. 19:1999;6195-6206
27. Fang W., Rivard J.J., Ganser J.A., et al. Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli. J Immunol. 155:1995;66-75
28. Binet J.L., Mentz F., Merle-Beral H. Apoptosis in blood diseases. Review new data. Hematol Cell Ther. 38:1996;253-264
29. Kan Z.Y., Chatterjee D., He D.M., et al. Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol Cell Biol. 15:1995;5849-5857
30. Wagner W., Prott F.J., Schonekas K.G. Amifostine A radioprotector in locally advanced head and neck tumors. Oncol Rep. 5:1998;1255-1257
31. Buntzel J., Schuth J., Kuttner K., et al. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care Cancer. 6:1998;155-160
32. Delioukina M.L., Prager D., Parson M., et al. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer. 94:2002;2174-2179
33. Freyer G., Hennebert P., Awada A., et al. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients a pilot study. Clin Cancer Res. 8:2002;95-102
34. Rick O., Beyer J., Schwella N., et al. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol. 12:2001;1151-1155
35. De Souza C.A., Santini G., Marino G., et al. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas A phase II study. Braz J Med Biol Res. 33:2000;791-798
36. Alberts D.S. Protection by amifostine of cyclophosphamide-induced myelosuppression. Semin Oncol. 26:1999;37-40
37. Mohr P., Makki A., Breitbart E., et al. Combined treatment of stage IV melanoma patients with amifostine and fotemustine - a pilot study. Melanoma Res. 8:1998;166-169
38. Budd G.T., Ganapathi R., Adelstein D.J., et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer. 80:1997;1134-1140
39. Giatromanolaki A., Sivridis E., Maltezos E., et al. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol. 29:2002;14-21
40. Capizzi R.L., Scheffler B.J., Schein P.S. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer. 72:1993;3495-3501
41. Shimura M., Osawa Y., Yuo A., et al. Oxidative stress as a necessary factor in room temperature-induced apoptosis of HL-60 cells. J Leukoc Biol. 68:2000;87-96
42. Shimura M., Okuma E., Yuo A., et al. Room temperature-induced apoptosis of Jurkat cells sensitive to both caspase-1 and caspase-3 inhibitors. Cancer Lett. 132:1998;7-16
43. Shimura M., Ishizaka Y., Yuo A., et al. Characterization of room temperature induced apoptosis in HL-60. FEBS Lett. 417:1997;379-384
44. Nishizawa Y., Saeki K., Hirai H., et al. Potent inhibition of cell density-dependent apoptosis and enhancement of survival by dimethyl sulfoxide in human myeloblastic HL-60 cells. J Cell Physiol. 174:1998;135-143
45. Saeki K., Yuo A., Kato M., et al. Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor beta 1 and overexpression of Bcl-2. J Biol Chem. 272:1997;20003-20010